Semax vs Noopept: evidence, cost, and legality

Which is better, Semax or Noopept?

The evidence is a tie: both are graded human observational from open Russian studies without placebo control (semax in stroke, Noopept in mild cognitive impairment after stroke or brain injury). Regulatory status breaks it. Semax has a pending path to lawful compounding after the July 2026 PCAC recommendation, while Noopept is not compoundable and its supplement sales are not an approved use, so product identity and purity are unverified. [1] [2] [3] [4] [5] [6]

How do Semax and Noopept compare?

Semax and Noopept compared by dimension
Dimension	SemaxFavored	Noopept
What it is [7] [8]	Heptapeptide analog of ACTH fragment 4-10 with a stabilizing Pro-Gly-Pro tail.	Synthetic dipeptide-like compound (phenylacetyl proline-glycine ethyl ester) related to piracetam, metabolized to cycloprolylglycine.
Proposed mechanism [7] [8] [9]	Raised hippocampal BDNF and trkB in rats after one intranasal dose; monoamine and anti-ischemic effects in rodents.	Raises BDNF and NGF in rodent hippocampus, enhances inhibitory transmission via alpha-7 nicotinic receptors on interneurons, and reduced tau hyperphosphorylation in a cell model.
Human evidence [1] [2] [3] [10]	Open comparative Russian studies in acute ischemic stroke and chronic cerebrovascular insufficiency; no blinding or placebo.	Open comparison with piracetam in mild cognitive disorders of vascular or traumatic origin, and an open study of 60 stroke patients reporting better MMSE scores after 2 months versus untreated controls.
Route [1] [2]	Intranasal drops (Russian product and most sold forms).	Oral tablet (Russian product) or capsule and powder (US supplement market).
Doses in the literature [1] [2]	Intranasal 12 to 18 mg per day for 5 to 10 days in acute stroke; roughly 0.2 to 2 mg per day for cognitive uses.	10 mg orally twice daily (20 mg per day) for 2 months.
FDA and compounding status [4] [5] [6] [11]	Removed from 503A Category 2 on April 15, 2026; PCAC recommended the 503A bulks list in July 2026; no final rule yet.	Never nominated for the 503A or 503B bulks lists and not on the Category 2 page; not compoundable. Sold as a supplement ingredient, which is not an approved use for a synthetic drug substance.
Access and cost [4] [6]	No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price.	Sold online as an unapproved supplement that is not verified for identity or purity; no licensed pharmacy or telehealth channel.
Reported side effects [1] [2]	Nasal irritation; anxiety, irritability, or insomnia reported anecdotally.	Irritability, sleep disturbance, and headache reported anecdotally; blood pressure increases in some patients in Russian reports.
WADA status [12]	Not named on the WADA Prohibited List; whether it falls under S0 (non-approved substances) is unclear, so tested athletes should confirm with their anti-doping organization.	Not named on the WADA Prohibited List; status unclear, so tested athletes should confirm with their anti-doping organization.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Semax and Noopept: grade, status, and cost
Attribute	Semax	Noopept
Class	Synthetic heptapeptide analog of ACTH fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro), a melanocortin derived nootropic and neuroprotective peptide	Synthetic dipeptide-like nootropic (proline-glycine ethyl ester with a phenylacetyl group), structurally related to piracetam
What it is	Nasal peptide registered in Russia; rodent brain growth factor data and open label Russian stroke trials; not FDA approved; recommended for compounding in 2026.	A dipeptide-like memory drug approved in Russia, with small open-label human studies, no placebo-controlled RCT indexed in English, and no FDA review.
Evidence	Evidence: Human observational evidence	Evidence: Human observational evidence
FDA status	Regulatory: Under FDA review	Regulatory: Unscheduled
Compounding	Semax was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023 and removed from it on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding semax to the 503A bulks list. As of the last verification date FDA has not published a final rule, so compounding pharmacies and state boards vary in whether they will fill it. It is not an FDA approved drug and is not eligible for 503B outsourcing. It is a registered prescription drug in Russia.	Noopept has never been nominated to or reviewed for the FDA 503A or 503B bulks lists and does not appear on the FDA Category 2 page (current as of April 22, 2026). It is not a component of any FDA approved drug. In the United States it is sold as a dietary supplement ingredient, but it is a synthetic drug substance approved in Russia and does not meet the definition of a dietary ingredient, so its sale as a supplement is not an approved use. It is not compoundable under 503A or 503B.
WADA	WADA: WADA status unclear	WADA: WADA status unclear
Routes	Intranasal drops (Russian product and most sold forms), Subcutaneous injection (as sold, no published human data)	Oral tablet (Russian prescription product, 10 mg), Oral capsule or powder (sold in the United States as an unapproved supplement ingredient), Sublingual and intranasal use reported anecdotally (no studies)
Typical cost	No lawful compounded price: Semax is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	Sold as an unapproved supplement in the United States at roughly 15 to 40 USD per month; not available through licensed pharmacy or telehealth channels.
Last verified	Sep 22, 2026	Sep 22, 2026

Has Semax been tested directly against Noopept?

No published trial has compared Semax and Noopept directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do Semax and Noopept cost?

Typical cost of Semax and Noopept
Dimension	Semax	Noopept
Typical cost	No lawful compounded price: Semax is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.	Sold as an unapproved supplement in the United States at roughly 15 to 40 USD per month; not available through licensed pharmacy or telehealth channels.
Price detail	Semax price by channel	Price index in progress

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Is semax or Noopept better for memory?

Neither has a placebo controlled trial for memory. Noopept's human data are in mild cognitive impairment after stroke or brain injury (better MMSE scores versus untreated controls in an open study of 60 patients); semax's are in stroke recovery. Evidence in healthy adults is absent for both. [1] [2] [3]

Is Noopept a peptide?

Not strictly. It is a small synthetic dipeptide-like molecule related to piracetam that is metabolized to the natural dipeptide cycloprolylglycine. Semax is a true seven amino acid peptide. [7] [8]

Is it legal to buy Noopept as a supplement?

It is sold that way, but a synthetic drug substance approved as a medicine in Russia does not meet the definition of a dietary ingredient, so the sale is not an approved use and products are not verified for identity or purity. Noopept also cannot be compounded, because it has never been nominated for the bulks lists. [5] [6]

Can a US pharmacy compound semax?

Not from bulk today. Semax came off FDA Category 2 on April 15, 2026 and PCAC recommended it for the 503A bulks list in July 2026, but the recommendation is advisory: until FDA publishes a final rule it is not on the bulks list, a 503A pharmacy has no federal basis to compound it from bulk, and state boards cannot authorize what federal law does not. [4] [11]

Are either banned in sport?

Neither is named on the WADA Prohibited List. Tested athletes should confirm with their anti-doping organization, because unapproved substances can fall under S0. [12]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Semax vs Noopept: evidence, cost, and legality. https://peptideagent.ai/compare/semax-vs-noopept
HTML link: <a href="https://peptideagent.ai/compare/semax-vs-noopept">Semax vs Noopept: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Semax vs Noopept

The short answer